Pharming Group N.V. (id:68 PHARM)
0.695 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/22/2024 8:29:50 AM)
Exchange closed, opens in 30 minutes
About Pharming Group N.V.
Market Capitalization 497.88M
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
| Headquarters (address) |
Darwinweg 24 Leiden 2333 CR Netherlands |
| Phone | 31 71 524 7400 |
| Website | https://www.pharming.com |
| Employees | 382 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | PHARM |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 0.647 - 1.22 |
| Market Capitalization | 497.88M |
| P/E trailing | 57.15 |
| P/E forward | -71.35 |
| Price/Sale | 1.74 |
| Price/Book | 1.63 |
| Beta | 0.811 |
| EPS | -0.030 |
| EPS Netherlands (ID:23, base:87) | 1.63 |